Abstract:Abstract Melasma is a common pigmentary disorder causing considerable cosmetic disfigurement and psychological distress. Treatment of melasma remains a challenge despite the availability of several therapeutic agents, due to its refractory and recurrent nature. Triple combination cream (TCC) consisting of hydroquinone (4%), tretinoin (0.05%) and fluocinolone acetonide (0.01%) is considered to be the first-line therapy for melasma. Ablative fractional lasers have been reported to be effective. We evaluated the effectiveness and safety of fractional ablative CO2 and TCC in melasma in a split-face randomized control study. Clinically diagnosed adult patients with symmetrical melasma were included in the study and were randomized to receive either fractional CO2 laser, once every 4 weeks plus TCC (group A), or TCC alone (group B) to either side of the face once daily for 12 weeks. The patients were evaluated every 4 weeks to determine treatment response and adverse effects, and were followed for another 12 weeks to determine relapse. There were 54 patients (19 male and 35 female; mean age 33.0 years, SD 7.7; age range 21–57 years). They had melasma for 0.5–15 years (mean duration 5.7 years, SD 3.5). Following treatment, the mean melanin index and modified Melasma Area and Severity Index (mMASI) scores decreased in both groups. The mean (SD) melanin index decreased from 46.5 (5.2) to 43.7 (5.6), P < 0.001, in group A, and from 47.0 (5.5) to 44.3 (5.5), P < 0.001, in group B. The mean (SD) mMASI decreased from 4.4 (1.8) to 2.8 (1.6), P < 0.001, in group A, and from 4.4 (1.9) to 3.2 (1.7), P < 0.001, in group B. The changes were statistically significant, but were comparable between the two groups (P = 0.47 and P = 0.20, respectively). However, improvement in Physician’s Global Assessment (PGA) was superior in group A vs. group B (60.8% vs. 39.1%, P < 0.001. Also, the mean (SD) patient self-assessment scores were 5.9 (2.0) and 4.6 (2.0) in group A and group B, respectively (P < 0.001) showing a better response in group A. There were no significant adverse effects. However, 67% of patients (34 of 51) had a relapse, with gradual increases in MI, mMASI, PGA and patient self-assessment scores in both groups during post-treatment follow-up. Therefore, the study has shown that fractional CO2 laser offers modest additional benefit and is safe in the treatment of melasma. Hence, further studies are required.

Evidence-Based Treatment for Melasma: Expert Opinion and a Review

Melasma: Treatment strategy

Topical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials

Medical therapies for Melasma

Best practices in the treatment of melasma with a focus on patients with skin of color

Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta‐analysis

Melasma hyperpigmentation: An overview of current topical therapeutics

Chemical peels for melasma in dark-skinned patients

A Combination Treatment of Drug‐laser‐photon for Melasma: A Retrospective Study of Clinical Cases

Melasma: an Up-to-Date Comprehensive Review

Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion

New oral and topical approaches for the treatment of melasma

Melasma: The need for tailored photoprotection to improve clinical outcomes

Latin American consensus on the treatment of melasma

Treatment of Melasma on Darker Skin Types: A Scoping Review

Efficacy of cysteamine and methimazole in treating melasma: A comparative narrative review

Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts

BC01 Evaluation of effectiveness of fractional ablative CO2 laser and triple combination cream in the treatment of melasma: a randomized controlled study

Efficacy and Safety of Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream in Chinese Patients with Melasma: a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study.

Melasma Revisited: National Survey Reveals How Dermatologists Diagnose and Treat This Complex Skin Condition

Comparison of the Efficacy of Melasma Treatments: A Network Meta-Analysis of Randomized Controlled Trials